Caribou’s CB-011 CAR-T Yields 83% CR, 91% MRD-Negativity in Phase 1 Trial
CRBU•CB-011’s single 450 million-cell dose in 12 BCMA-naïve patients achieved a 92% overall response rate, 83% complete responses and 91% MRD-negative status, with half maintaining ≥CR at 15 months. In 48 treated patients, CB-011 had no graft-versus-host disease and one therapy-related fatality.
1. Dose Escalation Efficacy Data
Caribou’s CaMMouflage phase 1 trial evaluated escalating doses of allogeneic CB-011 CAR-T therapy in BCMA-naïve relapsed/refractory multiple myeloma patients. At the recommended dose of 450 million cells, 12 patients achieved a 92% overall response rate, 83% complete response rate and 91% MRD negativity, with half maintaining ≥CR at 15 months.
2. Safety Profile
Across 48 patients treated in the dose escalation cohort, CB-011 demonstrated a manageable safety profile, with no graft-versus-host disease or severe neurotoxicity. There was one treatment-related death due to hematotoxicity, three unrelated deaths and limited high-grade cytokine release syndrome, infections and prolonged cytopenias at the recommended dose.
3. Patient Case Study
A 71-year-old relapsed/refractory multiple myeloma patient with eight prior therapies including an autologous anti-BCMA CAR-T achieved an early complete response after a single 450 million-cell CB-011 infusion. This response was ongoing at the data cutoff and correlated with robust CAR-T expansion and rapid serum free light chain reduction.
4. Upcoming Data and Presentation
These durability data will be presented orally on June 14, 2026 at the European Hematology Association meeting, with initial dose expansion results in both BCMA-naïve and BCMA-exposed patients expected in the second half of 2026.
